On Oct 31, major Wall Street analysts update their ratings for $Eli Lilly and Co (LLY.US)$, with price targets ranging from $975 to $1,100.
J.P. Morgan analyst Chris Schott maintains with a buy rating.
BofA Securities analyst Alec Stranahan maintains with a buy rating, and adjusts the target price from $1,150 to $1,100.
Barclays analyst Carter Gould maintains with a buy rating, and adjusts the target price from $1,025 to $975.
Wells Fargo analyst Mohit Bansal maintains with a buy rating, and maintains the target price at $1,000.
Truist Financial analyst Srikripa Devarakonda maintains with a buy rating, and adjusts the target price from $1,033 to $1,029.
Furthermore, according to the comprehensive report, the opinions of $Eli Lilly and Co (LLY.US)$'s main analysts recently are as follows:
Eli Lilly's recent quarter showed variability in the performance of Mounjaro and Zepbound. However, it has been clarified that the fluctuations in Mounjaro and Zepbound were due to inventory dynamics rather than supply or demand issues. Despite a slight downturn in the third quarter, the outlook on Eli Lilly remains positive, with just a slight reduction in the forecasts for Mounjaro and Zepbound.
Following the Q3 report, there's a recognition that significant efforts will be necessary in Q4 due to the $1B shortfall in tirzepatide. This comes as channel inventories fluctuate markedly and the push for direct-to-consumer efforts is delayed until mid-quarter.
Here are the latest investment ratings and price targets for $Eli Lilly and Co (LLY.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月31日，多家华尔街大行更新了$礼来 (LLY.US)$的评级，目标价介于975美元至1,100美元。
摩根大通分析师Chris Schott维持买入评级。
美银证券分析师Alec Stranahan维持买入评级，并将目标价从1,150美元下调至1,100美元。
巴克莱银行分析师Carter Gould维持买入评级，并将目标价从1,025美元下调至975美元。
富国集团分析师Mohit Bansal维持买入评级，维持目标价1,000美元。
储亿银行分析师Srikripa Devarakonda维持买入评级，并将目标价从1,033美元下调至1,029美元。
此外，综合报道，$礼来 (LLY.US)$近期主要分析师观点如下：
Eli Lilly最近的季度表现显示了Mounjaro和Zepbound的业绩波动。然而，已经明确指出Mounjaro和Zepbound的波动是由库存动态导致的，而不是由供应或需求问题引起的。尽管第三季度出现轻微下滑，对Eli Lilly的前景仍然积极，只是对Mounjaro和Zepbound的预测略有降低。
在Q3报告之后，人们认识到由于tirzepatide出现10亿美元的缺口，Q4将需要做出重大努力。这是因为渠道库存波动明显，直接面向消费者推广的努力直到季中才会延迟。
以下为今日5位分析师对$礼来 (LLY.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
